The announcement by Cipla Quality Chemicals about top management changes and delayed publication of financial results has thrown the drug company into the spotlight again after nearly three years of frequent profit warnings, inability to pay dividends and a shrinking share price at the Uganda Securities Exchange (USE).

Cipla Quality Chemicals is a Ugandan manufacturer of drugs for HIV/Aids treatment, malaria, TB and hepatitis medicines. It supplies drugs to Kenya, Tanzania, Rwanda, Botswana, South Africa, Namibia, Sierra Leone and Zambia.

The firm announced the retirement of chief executive officer Nevin Bradford at the beginning of August in a dramatic move that surprised investors after months of uncertainty about the firms commercial direction.

Bradford, a British national, joined the company in 2013 after serving in various pharmaceutical industry positions in Europe and Asia. He has been replaced by Ajay Kumar Pal, the firms chief operating officer who joined in February 2020, according to statutory disclosures.

Kumars appointment takes effect next month.

Dr John Collins Kamili was also appointed chief company pharmacist following the departure of Dr Samuel Opio in April this year. Whereas the companys full year results for March were scheduled for publication before end of July, the firm issued a notice last week alerting investors about delayed release of its financial results but did not give reasons for the unexpected development.

Copyright 2021 Nation Media Group. All Rights Reserved. Provided by SyndiGate Media Inc. (

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an as is and as available basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.